Publication

Video

Supplements and Featured Publications

BTK Inhibitors in B-Cell Lymphomas
Volume1
Issue 1

Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies

Author(s):

Lori A. Leslie, MD

In Partnership With:

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the utility of BTK inhibitors in B-cell malignancies.

BTK inhibitors target an enzyme that is necessary for B​-cell growth, says Leslie. ​Moreover, there are several approved indications ​for BTK inhibitors in chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, mantle cell lymphoma ​(MCL), and ​Waldenström macroglobulinemia.

Notably, ibrutinib (Imbruvica) ​and acalabrutinib (Calquence) ​are 2 BTK inhibitors that are approved for patients with B-cell malignancies. Moreover, zanubrutinib (Brukinsa) is currently approved in relapsed/refractory MCL and is the subject of ongoing investigation in other B-cell malignancies, Leslie concludes. 

Articles in this issue
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies
Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies
BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness
BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness
Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies
Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies
BTK Inhibitors Boost Outcomes in B-Cell Malignancies, But Challenges Remain
BTK Inhibitors Boost Outcomes in B-Cell Malignancies, But Challenges Remain
Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies
Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies
Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies
Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies
Building on Current Understandings of BTK Inhibition in CLL, MCL
Building on Current Understandings of BTK Inhibition in CLL, MCL
Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies
Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia
Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies
Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies
BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia
BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia
An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum
An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum
Exploring the Role of BTK Inhibitors in B-Cell Lymphomas
Exploring the Role of BTK Inhibitors in B-Cell Lymphomas
Related Videos
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Related Content
Acute Myeloid Leukemia | stock.adobe.com
December 20th 2024

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

Andre Henri Goy, MD
December 18th 2024

Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD

CP-CML | Image Credit: © สุพัฒตรา แสนพลี – stock.adobe.com
December 19th 2024

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

FDA
December 18th 2024

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

Orca-Q in Hematologic Malignancies | Image Credit: © Tatiana Shepeleva - stock.adobe.com
December 16th 2024

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT